Quotient Sciences have made a number of submissions through the HRA/MHRA Combined Ways of Working Pilot
The HRA and MHRA have been exploring opportunities to improve the service being offered for the approval and ongoing management of Clinical Trials of Medicinal Products (CTIMPs) and launched a pilot to test an integrated process – the Combined Ways of Working Pilot.
Quotient Sciences Significantly Expands Formulation and Manufacturing in UK
Quotient Sciences, a leading drug development services organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading, U.K., facility. The program’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing and significantly increased staffing levels.
Quotient Sciences Constructs State-of-the-Art Early-Phase Formulation and Manufacturing Facility in U.S.
Quotient Sciences announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, PA. The $15 million investment will create a center of excellence for early-phase formulation development and clinical trial manufacturing.
Arcinova, a Quotient Sciences business, increases GC-MS/MS capabilities with new system
Arcinova, a Quotient Sciences business, increase GC-MS/MS capabilities with purchase of new Thermo Scientific TSQ Duo triple quadrupole.
Pharmaterials rebrands to Quotient Sciences
Quotient Sciences announces that it has completed the integration and rebrand of Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization
Quotient Sciences announces it has acquired Pharmaterials, a CDMO based in Reading, UK. The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint and further supports the growth of Quotient’s Translational Pharmaceutics platform.